With BET inhibitors being able to sturdily repress both RAS and RhoA activities and with the fact that amoeboid movement facilitates the dissemination of DLBCL [16], it is plausible that combinative strategies tackling the mechanism adopted by lymphoma cells for their propagation may further improve the treatment outcome in these patients. This evidence concerns the gene RHOA and diffuse large B-cell lymphoma.